TY  - JOUR
AU  - Fernandez, Ana
AU  - Salgado, Mercedes
AU  - Garcia, Adelaida
AU  - Buxo, Elvira
AU  - Vera, Ruth
AU  - Adeva, Jorge
AU  - Jimenez-Fonseca, Paula
AU  - Quintero, Guillermo
AU  - Llorca, Cristina
AU  - Cañabate, Mamen
AU  - Lopez, Luis Jesus
AU  - Muñoz, Andres
AU  - Ramirez, Patricia
AU  - Gonzalez, Paula
AU  - Lopez, Carlos
AU  - Reboredo, Margarita
AU  - Gallardo, Elena
AU  - Sanchez-Canovas, Manuel
AU  - Gallego, Javier
AU  - Guillen, Carmen
AU  - Ruiz-Miravet, Nuria
AU  - Navarro-Perez, Victor
AU  - De-la-Camara, Juan
AU  - Ales-Diaz, Inmaculada
AU  - Pazo-Cid, Roberto Antonio
AU  - Carmona-Bayonas, Alberto
PY  - 2018
DO  - 10.1186/s12885-018-5101-3
UR  - http://hdl.handle.net/10668/13261
T2  - BMC cancer
AB  - Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to...
LA  - en
PB  - BMC Central
KW  - First-line chemotherapy
KW  - Gemcitabine
KW  - Metastatic pancreatic adenocarcinoma
KW  - Nab-paclitaxel
KW  - Real-life
KW  - Survival
KW  - Adult
KW  - Aged
KW  - Albumins
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Comorbidity
KW  - Deoxycytidine
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasm Staging
KW  - Paclitaxel
KW  - Pancreatic Neoplasms
KW  - Prognosis
KW  - Retrospective Studies
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Gemcitabine
TI  - Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
TY  - research article
VL  - 18
ER  -